Tech Transfer eNews Blog

Nationwide Children’s Hospital spins out company to produce gene therapies for drug developers


By Jesse Schwartz
Published: January 22nd, 2020

A company spun out of Nationwide Children’s Hospital is developing gene therapies for deadly inherited diseases.

Andelyn Biosciences will operate as a for-profit subsidiary of Nationwide. The start-up will build on the hospital’s advances in gene therapy by developing components for biotech and pharmaceutical companies that are running clinical trials on treatments for spinal muscular atrophy and other inherited diseases.

For years, Nationwide produced gene therapies for its research at a small clinical facility. As its work expanded and its industry partners began requesting products, the hospital added more production suites, and now Andelyn has plans to build a larger facility where it will develop gene therapies under contract with drug companies

“Part of the reason we feel we can do this is because of our track record of success in doing it at the scale we’ve been doing it for several years,” says Dennis Durbin, chief scientific officer at the Abigail Wexner Research Institute at Nationwide.

That track record includes a Phase I study led by researcher Jerry Mendell that paved the way for a new gene therapy for spinal muscular atrophy that was eventually licensed by biotech company AveXis.

“We’re tracking the growth, maturation and evolution of the field,” says Durbin. “Commercial-scale manufacturing represents one of the next significant barriers to the continued development of the field.”

Source: Biopharma Dive

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment